Erschienen in:
12.04.2019 | Letter to the Editor
Efficacy of immunotherapy, gut microbiota and impact of antibiotic use: are there confounding factors?
verfasst von:
G. Milano
Erschienen in:
Cancer Chemotherapy and Pharmacology
|
Ausgabe 1/2019
Einloggen, um Zugang zu erhalten
Excerpt
The inter-relationship between host microbiota and immunotherapy by checkpoint inhibitors (CPI) is currently actively investigated at experimental, pre-clinical and clinical levels [
1]. It has recently been shown that tumor expression of chemokines associated with T-cell infiltration can be stimulated by gut bacteria, and reduced by antibiotic treatment [
2]. Antibiotics may impair gut microbiota and their use is logically suspected to have a deleterious impact on the clinical outcome of patients treated with immune checkpoint inhibitors [
2]. There is by consequence a current view bridging antibiotic use, impaired gut microbiota and subsequently negative impact on immune checkpoint inhibitors efficacy which stimulates clinical investigations [
3]. Specific clinical studies indicate a poor clinical benefit in patients undergoing immunotherapy with a history of previous antibiotic use [
4]. …